Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021


Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021, on Tuesday, November 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Conference Call Details

To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 7744465. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 7744465.

To access the live and subsequently archived webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events.

About Omeros Corporation

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement, and Omeros is seeking FDA approval of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Additional narsoplimab programs are focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors.


These press releases may also interest you

at 04:00
The expanded water storage reservoir of the Waterval Islamic Institute in Sandton (Gauteng), South Africa, was...

at 04:00
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against agilon health, inc. ("agilon" or "the Company") and certain of its officers. Class...

at 03:23
The total number of votes in EQT AB (publ) ("EQT") changed during March 2024 as a result of a conversion of 348,106 class C shares to 348,106 ordinary shares. The conversion was made pursuant to EQT's previous Share Program. The total...

at 03:20
Due to a conversion of shares from Series A to Series B in accordance with AB SKF's Articles of Association, the Company confirms the following. As per 28 March 2024, the Company's share capital amounts to SEK 1,138,377,670 and the total number of...

at 03:00
Caledonia Mining Corporation Plc ("Caledonia" or the "Company")  announces its operating and financial results for the year ended December 31, 2023 (the "Year"). Further information on the financial and operating results for the Year and the quarter...

at 03:00
This week marks the launch of The Lenserf Group's pioneering "Exceed Your Potential Academy" for over 20 student interns from six Historically Black Colleges and Universities (HBCUs). This innovative, employer-sponsored program offers an 8-week...



News published on and distributed by: